Stocks · News reference
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 12:23 PM
- Checked
- Aug 25, 2026, 12:23 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Carl Icahn Trims JetBlue, AEP Stakes While Sitting Out New Stock Bets
Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power. The rest of his portfolio is unchanged.
Read original at benzinga8-K/A filing — Bausch & Lomb Corp (BLCO)
Filed: 2026-08-12 AccNo: 0000950103-26-012223 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgar